About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/24/2021.
This website is for US healthcare professionals

Log In to Bolder Science


Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/24/2021.

Feasibility of Medical Abortion by Telemedicine in Mexico

Clinicaltrials.gov identifier NCT03931460

Recruitment Status Recruiting

First Posted April 30, 2019

Last update posted June 16, 2020

Study Description

Brief summary:

This study is designed to obtain preliminary data on the safety, acceptability, and feasibility of direct-to-consumer telemedicine abortion in Mexico.

  • Condition or Disease:Pregnancy
  • Intervention/Treatment: Drug: Medical Abortion
  • Phase: N/A
Detailed Description


Study Design
  • Study Type: Observational
  • Estimated Enrollment: 100 participants
  • Observational Model: Case-Only
  • Time Perspective: Prospective
  • Official Title: Feasibility of Medical Abortion by Telemedicine in Mexico
  • Actual Study Start Date: April 2019
  • Estimated Primary Completion Date: March 2021
  • Estimated Study Completion Date: March 2021
Outcome Measures
  • Primary Outcome Measures: 1. Number of participants with adverse events as a measure of safety and tolerability [ Time Frame: 1 year ]
    Adverse Events
Eligibility Criteria
  • Ages Eligible for Study: 10 to 50 Years (Child, Adult)
  • Sexes Eligible for Study: Female
  • Accepts Healthy Volunteers: Yes
  • Sampling Method: Non-Probability Sample
  • Study Population: Women seeking abortion

Inclusion Criteria:

- Woman is pregnant and desires a medical abortion by remote consult (TeleILE)

- Woman has access to internet or equipment for a remote consult

- Woman can provide address to which abortifacient medications will be mailed

- Woman reports no contraindications to medical abortion

- The study site does not suspect an ectopic pregnancy or nonviable pregnancy

- The gestational age allows sufficient time for the woman to take the mifepristone on
or before 70 days of gestation

- A feasible plan is made that the woman agrees to confirm complete abortion and to seek
care to manage incomplete abortion complications

- The woman understands and is likely to comply with study instructions and has granted
informed consent to participate in the study.

Exclusion Criteria:

- Medically ineligible for procedure.

Contacts and Locations

Contact: Melanie Pena, MPH, MA (212) 448-1230 mpena@gynuity.org

Contact: Manuel Bousiéguez, MBA (212) 448-1230 mbousieguez@gynuity.org


Mexico, Chiapas
Clinica AMASS
San Cristobal de las Casas

Mexico, Yucatan
Servicios Humanitarios en Salud Sexual y Reproductiva (SHSSR)

Atención Integral en Ginecología,Medieg A.C.
Mexico City

Centro de Atención Integral a la Pareja, A.C. (CIPA)
Mexico City

Mexico City

Sponsors and Collaborators

Gynuity Health Projects

More Information
  • Responsible Party: Gynuity Health Projects
  • ClinicalTrials.gov Identifier: NCT03931460 History of Changes
  • Other Study ID Numbers: 1045
  • First Posted: April 30, 2019 Key Record Dates
  • Last Update Posted: June 16, 2020
  • Last Verified: June 2020
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No